Lazard, Inc. LAZ
NYSE · XNYS · stock · Investment Advice
Chart by TradingView
4/9
Piotroski F — financial health
—
Altman Z″ — distress risk
78.8%
Dividend payout · stretched
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $3.2B | $236.8M | — | $487.4M | $906.3M |
| 2024 | $3.1B | $279.9M | — | $697.3M | $680.7M |
| 2023 | $2.6B | -$75.5M | — | $136.4M | $482.2M |
| 2022 | $2.9B | $357.5M | — | $784.5M | $675.4M |
| 2021 | $3.3B | $528.1M | — | $826.4M | $1.1B |
| 2020 | $2.6B | $402.5M | — | $511.6M | $999.4M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Source: SEC EDGAR filings · CIK 0001311370 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.